Ph.D: University of Guelph, Canada
M.V.Sc: Indian Veterinary Research Institute, India
D.V.M: MAFSU, India
Lab website: http://koti-lab.ca
I am a Veterinarian with Ph.D. in Molecular Immunology. Research in my lab is focused on delineating the role of tumor immune microenvironment in cancer progression and treatment response. Our long term goal is to identify genomic correlates of prognostic and predictive immune biomarkers that reflect differential pre-treatment tumour immune contexture. Identification of these biomarkers will inform decisions for individualized treatment approaches, augment design of novel immunomodulatory therapies and enhance response to conventional chemotherapies.
Our research focusses on investigating the interactions between host immune physiology and cancer cell intrinsic features that determine response to immunomodulatory treatments. Using bladder and ovarian cancer patient derived specimens, cell lines and immunocompetent mouse models to study the tumour-immune interactions, the primary goals of our research program are,
- To define influence of sex differences and aging in anti-tumour immunity and treatment outcomes.
- To delineate the role of cancer cell intrinsic genetic events in the evolution of variable pre-treatment states of the tumor immune microenvironment.
- To develop combination immune priming approaches to enhance sensitivity to chemotherapy and immunomodulatory therapy in cancer.
Dr. Koti is a Veterinarian with PhD in Immunology. She is currently an Assistant Professor in the Departments of Biomedical and Molecular Sciences and Obstetrics and Gynaecology at Queen’s University. She is also cross-appointed to the Department of Urology and is a member of the Division of Cancer Biology and Genetics at QCRI.
Madhuri Koti* and D. Robert Siemens. Sex and gender differences in cancers of the genitourinary tract: the need to consider immune divergence. (2021). European Urology. DOI:https://doi.org/10.1016/j.eururo.2021.10.026. PMID: 34750036.
Stephen Chenard, Chelsea Jackson, Thiago Vidotto, Lina Chen, Céline Hardy, Tamara Jamaspishvilli, David Berman, D. Robert Siemens, Madhuri Koti*. Sexual dimorphism in outcomes of non-muscle invasive bladder cancer: a role of CD163+ M2 macrophages, B cells and PD-L1 immune checkpoint. (2021). European Urology: Open Science. DOI:https://doi.org/10.1016/j.euros.2021.05.002. PMID: 34337534.
Stephen Chenard, D. Robert Siemens, Madhuri Koti*. The CXCR3alt-CXCL11 axis in bladder cancer: potential for prediction of neoadjuvant chemotherapy response. (2021). Commentary/Research Highlight. Molecular and Cellular Immunology. https://www.nature.com/cmi/news-and-comment/. https://rdcu.be/ckCNn. PMID: 33990777.
Rachel Sue-A-Quan, Palak G Patel, Noor Shakfa, May-Phyo Nyi Nyi, Afrakoma Afriyie-Asante, Eun Young Kang, Martin Köbel, Madhuri Koti*. Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. (2021). Gynecologic Oncology. DOI: 10.1016/j.ygyno.2021.05.010. PMID: 34088514.
Alvaro Morales, D. Robert Siemens and Madhuri Koti. At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer. (2021). A commentary in, Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2020.10.009. PMID: 33218921.
Madhuri Koti*, Molly A. Ingersoll, Shilpa Gupta, Christa M. Lam, Xue Li, Ashish M. Kamat, Peter C. Black and D. Robert Siemens. Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment. (2020). European Urology:Oncology. DOI: https://doi.org/10.1016/j.euo.2020.08.013. PMID: 32967818.
Madhuri Koti*, Alvaro Morales, Charles H. Graham, D. Robert Siemens. BCG vaccine and COVID-19: Implications for infection prophylaxis and cancer immunotherapy. (2020). Journal for ImmunoTherapy of Cancer. DOI:10.1136/ jitc-2020-001119. PMID: 32636240.
Sarah Nersesian, Noor Shakfa, Nichole Peterson, Thiago Vidotto, Afrakoma AfriyieAsante, Elizabeth Lightbody, Madhuri Koti*. Chemotherapy induced immunogenic cell death alters response to exogenous activation of STING pathway and PD-L1 immune checkpoint blockade in a syngeneic murine model of ovarian cancer. (2019). https://www.biorxiv.org/content/10.1101/824094v1.
Madhuri Koti*, Stephen Chenard, Sarah Nersesian, Thiago Vidotto, Alvaro Morales, D. Robert Siemens. Investigating the STING pathway to explain mechanisms for BCG failures in non-muscle invasive bladder cancer: prognostic and therapeutic implications. (2019). Bladder Cancer. DOI: 10.3233/BLC-190228.
Thiago Vidotto, Sarah Nersesian, Charles H. Graham, D. Robert Siemens, Madhuri Koti*. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. (2019). Journal for ImmunoTherapy of Cancer. DOI: 10.1186/s40425-019-0619-8. PMID:31174611.
Vidotto, T., Saggioro, F. P., Jamaspishvili, T., Chesca, D. L., Picanco-Albuquerque, C. G., Reis, R. B., Graham,C. H., D. M. Berman, Siemens, D. R., Squire, J. A., Koti, M*. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. (2019). Prostate. DOI: 10.1002/pros.23808. PMID: 30999388
Natasha Vitkin, Sarah Nersesian, D. Robert Siemens, Madhuri Koti*. The tumour immune contexure of prostate cancer. (2019). Frontiers in Immunology. DOI: 10.3389/fimmu.2019.00603. PMID: 30984182
Abdi Ghaffari, Nichole Peterson, Kasra Khalaj, Natasha Vitkin, Andrew Robinson, Julie-Ann Francis, Madhuri Koti*. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. (2018). British Journal of Cancer. DOI 10.1038/s41416-018-0188-5.
Cole Clifford, Natasha Vitkin, Gillian Reid-Schachter, Julie-Ann Francis, Madhuri Koti*. Multi-omics in high-grade serous ovarian cancer: biomarkers from genome to the immunome. (2018). American Journal of Reproductive Immunology. May 21:e12975. doi: 10.1111/aji.12975. PMID: 29781548
Madhuri Koti*, Amanda Shou Xu, Kevin Yi Mi Ren, Kash Visram, Runhan Ren, David Berman, D. Robert Siemens. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer. (2017). Bladder Cancer. vol. 3, no. 4, pp. 259-267.
Runhan Ren, Kathrin Tyrishkin, Charles H. Graham, Madhuri Koti, D. Robert Siemens. Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. (2017). Oncotarget. Aug 9;8(41):70982-71001.PMID: 29050337
Katrina K. Au, Nichole Peterson, Peter Truesdell, Gillian Reid-Schachter, Kasra Khalaj, Runhan Ren, Julie-Ann Francis, Charles H Graham, Andrew W. Craig and Madhuri Koti*. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. (2017). Gynecologic Oncology. Jun;145(3):436-445. PMID: 28318643
Katrina Au, Cécile Le Page, Runhan Ren, Liliane Meunier, Kathrin Tryshkin, Nichole Peterson, Jennifer Kendall-Dupont, Timothy Childs, Julie-Ann Francis, Charles H Graham, Andrew B. Craig, Jeremy A. Squire, Anne-Marie Mes-Masson, and Madhuri Koti*. (2016). STAT1 associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology: Clinical Research. Sep 19;2(4):259-270. PMID: 27917296
Runhan Ren, Madhuri Koti, Thomas Hamilton, Charles H. Graham, Jasmir G. Nayak, Jas Singh, Darrel E. Drachenberg, D. Robert Siemens. A primer on tumour immunology and prostate cancer immunotherapy. (2016). Can Urol Assoc J. 10 (1-2). PMID: 26977209
Madison Black, Ivraym Barsoum, Tiziana Cotechini, Peter Truesdell, D. Robert Siemens, Madhuri Koti, Andrew Craig, Charles Graham. Activation of the PD-1/PD-L1 immune checkpoint confers chemoresistance and promotes tumor metastasis. (2016). Oncotarget. PMID: 26859684
Katrina Au, Juliana Josahikan, Julie-Ann Francis, Jeremy A. Squire, Madhuri Koti*. Current state of biomarkers in ovarian cancer prognosis. (2015). Future Oncology. Dec 11 (23); 3187-95. PMID: 26551891
Madhuri Koti*, Alex Siu, Isabelle Clement, Mallikarjun Bidarimath, Gulisa Turashvilli, Andrew Edwards, Anne-Marie Mes Masson, Jeremy A. Squire. A distinct pre-existing inflammatory tumor microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. (2015). British Journal of Cancer. March 31; 112, 1215-1222. PMID: 26695556
Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. (2014). Cancer Research. Dec 15;74(24):7185-90. PMID: 25344227.
Madhuri Koti, Surinder S. Saini, Ashish Sachan and Azad K. Kaushik. Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines. (2014). Antibodies. 3, 205-214; doi:10.3390/antib3020205. http://www.mdpi.com/2073-4468/3/2/205.
Jeff W Martin, Susan Chilton-MacNeill, Madhuri Koti, Andre J van Wijnen, Jeremy A Squire, Maria Zielenska. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. (2014). PLoS One. May 16;9(5). PMID: 24835790.
Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. (2013). BMC Cancer. Nov 16;13:549. PMID: 24237932.
Geraci J, Dharsee M, Nuin P, Haslehurst A, Koti M, Feilotter HE, Evans K. Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems. (2014). Bioinformatics. Mar 1;30(5):712-8. PMID: 24149051.
Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. (2012). BMC Cancer. Mar 19;12:91. PMID: 22429801.
Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. (2011). Cancer Genetics. Oct;204(10):525-35. PMID: 22137482.
Koti M, Kataeva G, Kaushik AK. A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1. (2011). Vaccine. Oct 19;29(45):7905-12. PMID: 21872632.
Koti M, Kataeva G, Kaushik AK. Novel atypical nucleotide insertions specifically at VH-DH junction generate exceptionally long CDR3H in cattle antibodies. (2010). Molecular Immunology. Jul;47(11-12):2119-28. PMID: 20435350.
Koti M, Farrugia W, Nagy E, Ramsland PA, Kaushik AK. Construction of single-chain Fv with two possible CDR3H conformations but similar inter-molecular forces that neutralize bovine herpesvirus 1. (2010). Molecular Immunology. Feb;47(5):953-60. PMID: 20006385.
Kaushik AK, Kehrli ME Jr, Kurtz A, Ng S, Koti M, Shojaei F, Saini SS. Somatic hypermutations and isotype restricted exceptionally long CDR3H contribute to antibody diversification in cattle. (2009). Veterinary Immunology and Immunopathology. Jan 15;127(1-2):106-13. PMID: 19012969.
Koti M, Kataeva G, Kaushik AK. Organization of D(H)-gene locus is distinct in cattle. (2008). Dev Biol (Basel). ;132:307-13. PMID: 18817318.